SRES-422-119
Resolution agreed to in Senate without amendment and with a preamble by Unanimous Consent.
Sponsored by Elizabeth Warren (D-MA)
What it does
This resolution expresses the Senate's support for designating September 2025 as "Polycystic Ovary Syndrome (PCOS) Awareness Month." It recognizes PCOS as a serious medical condition caused by a hormone imbalance, with symptoms including infertility, weight gain, excess hair growth, and acne. As a simple resolution, it does not create law, appropriate funds, or establish any federal program.
Who benefits
People with PCOS — estimated at roughly 5 million in the U.S. — who may benefit from increased public awareness and reduced stigma. Patient advocacy organizations focused on PCOS and related reproductive health conditions. Healthcare providers who may see increased patient engagement and earlier diagnoses. Researchers who may gain visibility for PCOS-related funding needs.
Who is hurt
No group faces a direct material harm from this resolution. There are no mandates, spending changes, or regulatory effects. Opportunity cost critics might note that Senate floor time is a finite resource, though simple resolutions typically pass by unanimous consent with minimal time expenditure, as this one did.
Supporters argue
Supporters argue that PCOS is one of the most common hormonal disorders affecting people of reproductive age, yet remains widely underdiagnosed and poorly understood by the public. They contend that formal congressional recognition raises awareness, encourages earlier diagnosis, and signals support for expanded research funding — outcomes that could meaningfully improve health outcomes for millions of Americans living with the condition.
Opponents argue
Opponents might argue that symbolic resolutions without accompanying funding, research directives, or policy changes produce no measurable improvement in patient outcomes or research investment. They contend that designating awareness months has become routine to the point of diminishing returns, and that congressional attention to PCOS would be better directed toward substantive legislation such as dedicated NIH funding or improved insurance coverage for diagnostic testing.